- Molecular NameAlendronate
- SynonymAcide Alendronique [INN-French]; Acido Alendronico [INN-Spanish]; Acidum Alendronicum [INN-Latin]; Alendronate Sodium; Alendronic acid
- Weight249.096
- Drugbank_IDDB00630
- ACS_NO66376-36-1
- Show 3D model
- LogP (experiment)-3.198
- LogP (predicted, AB/LogP v2.0)-5.64
- pka2.7, 8.7, 10.5, 11.6
- LogD (pH=7, predicted)-9.23
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.6
- LogSw (predicted, AB/LogsW2.0)4011.2
- Sw (mg/ml) (predicted, ACD/Labs)428.42
- No.of HBond Donors7
- No.of HBond Acceptors8
- No.of Rotatable Bonds5
- TPSA180.93
- StatusFDA approved
- AdministrationN/A
- PharmacologyA bisphosphonate drug used for osteoporosis and several other bone diseases.
- Absorption_value1.0
- Absorption (description)Alendronate is poorly absorbed after oral administration and absorption is decreased by food, especially products containing calcium or other polyvalent cations.
- Caco_2N/A
- Bioavailability1.0
- Protein binding78.0
- Volume of distribution (VD)0.44 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt does not appear to be metabolised
- Half lifeFollowing a single 10 mg IV infusion over 2 hours and a 10 mg oral dose daily for >3 years.
- ExcretionThe drug is rapidly cleared from plasma and about half of the absorbed dose is excreted in urine with the remainder being sequestered to bone for a prolonged period. Approximately, 45% is excreted in urine in the first 8 h after an intravenous dose and then 5% is excreted much more slowly between 8 and 72 h. The drug is probably bound to the mineral phase of the skeleton and of that retained, approximately one-third is excreted over the first 6 months.
- Urinary Excretion44.9
- Clerance1.11 ml.min-1.kg-1
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A